Benzinga··PrnewswireCitius Oncology Posts Maiden Revenue of $3.9M From LYMPHIR Launch
Citius Oncology reports maiden revenue of $3.9M from LYMPHIR immunotherapy launch in December 2025, marking transition to commercial-stage biopharmaceutical company.
CTXRCTORnet lossFDA approval